Cargando…

Detection of minimal residual disease by next generation sequencing in AL amyloidosis

Detalles Bibliográficos
Autores principales:	Sarosiek, Shayna, Varga, Cindy, Jacob, Allison, Fulciniti, Maria Teresa, Munshi, Nikhil, Sanchorawala, Vaishali
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8217177/ https://www.ncbi.nlm.nih.gov/pubmed/34155198 http://dx.doi.org/10.1038/s41408-021-00511-6

Ejemplares similares

Treatment Options For Relapsed/refractory Systemic Light-Chain (AL) Amyloidosis: Current Perspectives
por: Sarosiek, Shayna, et al.
Publicado: (2019)

Evaluation of minimal residual disease using next-generation flow cytometry in patients with AL amyloidosis
por: Kastritis, Efstathios, et al.
Publicado: (2018)

Comparing measures of hematologic response after high-dose melphalan and stem cell transplantation in AL amyloidosis
por: Sarosiek, Shayna, et al.
Publicado: (2020)

Differences in the cytogenetic underpinnings of AL amyloidosis among African Americans and Caucasian Americans
por: Staron, Andrew, et al.
Publicado: (2022)

Improvement in Clinic Efficiency, Patient Satisfaction, and Overcoming Unique Challenges in the Era of COVID-19 with Implementation of Subcutaneous Daratumumab in Patients with Multiple Myeloma (MM) and Light Chain (AL) Amyloidosis
por: Hughes, David, et al.
Publicado: (2020)

Summary of the EHA-ISA Working Group Guidelines for High-dose Chemotherapy and Stem Cell Transplantation for Systemic AL Amyloidosis
por: Sanchorawala, Vaishali
Publicado: (2022)

Left Atrial Mechanics Associates With Paroxysmal Atrial Fibrillation in Light-Chain Amyloidosis Following Stem Cell Transplantation
por: Lohrmann, Graham, et al.
Publicado: (2020)

Minimal residual disease negativity by next-generation flow cytometry is associated with improved organ response in AL amyloidosis
por: Palladini, Giovanni, et al.
Publicado: (2021)

Race/ethnicity in systemic AL amyloidosis: perspectives on disease and outcome disparities
por: Staron, Andrew, et al.
Publicado: (2020)

Exploiting endogenous and therapy-induced apoptotic vulnerabilities in immunoglobulin light chain amyloidosis with BH3 mimetics
por: Fraser, Cameron S., et al.
Publicado: (2022)

Marked progress in AL amyloidosis survival: a 40-year longitudinal natural history study
por: Staron, Andrew, et al.
Publicado: (2021)

Health-Related Quality of Life Instruments for Clinical Trials in AL Amyloidosis: Report from the Amyloidosis Forum HRQOL Working Group
por: Rizio, Avery A, et al.
Publicado: (2023)

Predictors of treatment response and survival outcomes in patients with advanced cardiac AL amyloidosis
por: Gustine, Joshua N., et al.
Publicado: (2023)

Sars-Cov-2 Infection and Systemic Light Chain Amyloidosis: The International Society of Amyloidosis' Survey
por: Milani, Paolo, et al.
Publicado: (2020)

Venetoclax for the treatment of translocation (11;14) AL amyloidosis
por: Sidiqi, M. Hasib, et al.
Publicado: (2020)

Evaluating the Amyloidosis Speakers Bureau: the influence of amyloidosis patients’ narratives on medical students’ knowledge, attitudes, and behavioral intent
por: Adebayo, Adebanke L., et al.
Publicado: (2023)

Racial disparities in patients diagnosed with light chain (AL) amyloidosis
por: D’Souza, Anita, et al.
Publicado: (2021)

AL Amyloidosis Presenting with Yellow Discolouration of the Skin with Dermoscopic Findings
por: Acar, Ayda, et al.
Publicado: (2023)

A longitudinal evaluation of health‐related quality of life in patients with AL amyloidosis: associations with health outcomes over time
por: Sanchorawala, Vaishali, et al.
Publicado: (2017)

Ethnic Disparities in AL Amyloidosis Outcomes Among Hospitalized Patients in the United States
por: Al Hadidi, Samer, et al.
Publicado: (2022)

Patient-reported burden of hereditary transthyretin amyloidosis on functioning and well-being
por: Lovley, Andrew, et al.
Publicado: (2021)

First third-generation CAR T cell application targeting CD19 for the treatment of systemic IgM AL amyloidosis with underlying marginal zone lymphoma
por: Korell, Felix, et al.
Publicado: (2023)

High response rates with single-agent belantamab mafodotin in relapsed systemic AL amyloidosis
por: Khwaja, Jahanzaib, et al.
Publicado: (2022)

The Role of Kidney Transplantation in Monoclonal Ig Deposition Disease
por: Angel-Korman, Avital, et al.
Publicado: (2020)

Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma
por: Medina, Alejandro, et al.
Publicado: (2020)

The impact and importance of achieving a complete haematological response prior to renal transplantation in AL amyloidosis
por: Cohen, Oliver C., et al.
Publicado: (2020)

Light chain amyloidosis associated with Waldenström macroglobulinemia: treatment and survival outcomes
por: Gustine, Joshua N., et al.
Publicado: (2022)

Dynamic monitoring of myeloma minimal residual disease with targeted mass spectrometry
por: Noori, Somayya, et al.
Publicado: (2023)

Standardized Minimal Residual Disease Detection by Next-Generation Sequencing in Multiple Myeloma
por: Yao, Qiumei, et al.
Publicado: (2019)

Minimal Residual Disease Monitoring with Next-Generation Sequencing Methodologies in Hematological Malignancies
por: Sánchez, Ricardo, et al.
Publicado: (2019)

Venetoclax induces deep hematologic remissions in t(11;14) relapsed/refractory AL amyloidosis
por: Premkumar, Vikram J., et al.
Publicado: (2021)

Correlation Between 24-Hour Urine Protein and Random Urine Protein-Creatinine Ratio in Amyloid Light-Chain Amyloidosis
por: Mendelson, Lisa, et al.
Publicado: (2022)

Psychometric validation of the SF-36 Health Survey in light chain amyloidosis: results from community-based and clinic-based samples
por: White, Michelle K, et al.
Publicado: (2017)

Outcomes of t(11;14) light chain (AL) amyloidosis after autologous stem cell transplantation: benchmark for new therapies
por: Bal, Susan, et al.
Publicado: (2023)

Next-generation sequencing in the diagnosis and minimal residual disease assessment of acute myeloid leukemia
por: Levine, Ross L., et al.
Publicado: (2019)

Minimal residual disease negativity by next‐generation flow in non‐CR myeloma patients
por: Kim, Sung‐Min, et al.
Publicado: (2020)

Rare manifestation of multiple endocrine neoplasia type 2A & cutaneous lichen amyloidosis in a family with RET gene mutation
por: Birla, Shweta, et al.
Publicado: (2014)

A randomized phase 3 study of ixazomib–dexamethasone versus physician’s choice in relapsed or refractory AL amyloidosis
por: Dispenzieri, Angela, et al.
Publicado: (2021)

Assessing sleep among the next generation of healthcare delivery professionals
por: Rossener, Raissa, et al.
Publicado: (2020)

Minimal residual disease detection by next-generation sequencing in multiple myeloma: Promise and challenges for response-adapted therapy
por: Ferla, Valeria, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_q648r5mhvujqp7irfn1k4a8qdr